Skip to content

Study · Animal study (in vivo) · rat · 2006

6 results

Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.

Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF

Journal of neurochemistry1 Apr 2006Cited by 16 (Europe PMC)

PMID16635254 (opens in a new tab)DOI10.1111/j.1471-4159.2006.03658.x (opens in a new tab)PepBankPUB-16635254
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats, intranasal Semax at two doses increased BDNF levels in the basal forebrain after 3 h.

    In plain wordsIn rats, Semax given through the nose raised BDNF protein in the basal forebrain after 3 hours.

    Peptide
    Semax
    Outcome
    IncreaseBDNF level in basal forebrain
    Study

    ratn: not reported in source

    In vivo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 and 250 microg/kg bodyweight · intranasal · 3 hAs given in this study (rat).

    Source sentences

    Summary
    Sandwich immunoenzymatic analysis revealed that Semax applied intranasally at 50 and 250 microg/kg bodyweight resulted in a rapid increase in BDNF levels after 3 h in the basal forebrain, but not in the cerebellum.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats, intranasal Semax did not increase BDNF levels in the cerebellum, in contrast to the basal forebrain.

    In plain wordsIn rats, Semax given through the nose did not raise BDNF protein in the cerebellum.

    Peptide
    Semax
    Outcome
    No significant changeBDNF level in cerebellum
    Study

    ratn: not reported in source

    In vivo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 and 250 microg/kg bodyweight · intranasal · 3 hAs given in this study (rat).

    Source sentences

    Summary
    Sandwich immunoenzymatic analysis revealed that Semax applied intranasally at 50 and 250 microg/kg bodyweight resulted in a rapid increase in BDNF levels after 3 h in the basal forebrain, but not in the cerebellum.
  3. 03LabEx vivo tissueActivity measurement

    Binding of tritium-labelled Semax to rat basal forebrain membranes was time dependent, specific and reversible.

    In plain wordsIn lab tests, Semax bound to rat brain cell membranes in a specific and reversible way.

    Peptide
    Semax
    Outcome
    Not applicableBinding of tritium-labelled Semax
    Study

    ratn: not reported in source

    Cell membranes isolated from rat basal forebrain
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The binding of tritium-labelled Semax was found to be time dependent, specific and reversible.
    1 context sentence
    Summary · context
    In addition, we examined whether cell membranes isolated from this brain region contained binding sites for Semax.
  4. 04LabEx vivo tissueActivity measurement

    Specific Semax binding to rat basal forebrain membranes required calcium ions.

    In plain wordsIn lab tests, Semax binding to rat brain cell membranes needed calcium ions.

    Peptide
    Semax
    Outcome
    Not applicableCalcium dependence of Semax binding
    Study

    ratn: not reported in source

    Cell membranes isolated from rat basal forebrain
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Specific Semax binding required calcium ions
    1 context sentence
    Summary · context
    In addition, we examined whether cell membranes isolated from this brain region contained binding sites for Semax.
  5. 05LabEx vivo tissueActivity measurement

    Semax bound to rat basal forebrain membranes with a dissociation constant of 2.4 nm (mean).

    In plain wordsIn lab tests, Semax bound to rat brain cell membranes with a measured binding strength (KD) of 2.4 nm.

    Peptide
    Semax
    Outcome
    Not applicableDissociation constant (KD) of Semax binding
    Study

    ratn: not reported in source

    Cell membranes isolated from rat basal forebrain
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    KD
    2.4 nm
    rat basal forebrain membranes

    Source sentences

    Summary
    a mean+/-SEM dissociation constant (KD) of 2.4+/-1.0 nm
    1 context sentence
    Summary · context
    In addition, we examined whether cell membranes isolated from this brain region contained binding sites for Semax.
  6. 06LabEx vivo tissueActivity measurement

    Rat basal forebrain membranes had a BMAX value for Semax binding of 33.5 fmol/mg protein (mean).

    In plain wordsIn lab tests, rat brain cell membranes had a maximal Semax binding capacity of 33.5 fmol per mg protein.

    Peptide
    Semax
    Outcome
    Not applicableMaximal binding capacity (BMAX) of Semax
    Study

    ratn: not reported in source

    Cell membranes isolated from rat basal forebrain
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    BMAX
    33.5 fmol/mg protein
    rat basal forebrain membranes

    Source sentences

    Summary
    a BMAX value of 33.5+/-7.9 fmol/mg protein.
    1 context sentence
    Summary · context
    In addition, we examined whether cell membranes isolated from this brain region contained binding sites for Semax.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.